[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100-105.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):100-105.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
点击复制

广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第2期
页码:
100-105
栏目:
出版日期:
2016-03-25

文章信息/Info

Title:
Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy
作者:
李景涛;  邓垒;  张文珏;  肖泽芬;  冯勤付;  陈东福;  梁军;  吕纪马;  周宗玫
100021 北京, 北京协和医学院中国医学科学院肿瘤医院放疗科
Author(s):
Li Jingtao;  Deng Lei;  Zhang Wenjue;  Xiao Zefen;  Feng Qinfu;  Chen Dongfu;  Liang Jun;  Lyu Jima;  Zhou Zongmei
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Pecking Union Medical College, Beijing 100021, China
关键词:
癌; 小细胞; 放射疗法; 辐射性肺炎; 调强放射治疗
Keywords:
Carcinoma;  small cell; Radiotherapy; Radiation pneumonitis; Intensity-modulated radiation therapy
DOI:
10.3760/cma.j.issn.1673-4114.2016.02.003
摘要:
目的 评价广泛期小细胞肺癌(SCLC)化疗后接受胸部IMRT,发生放射性肺炎(RP)的临床和剂量-体积因素。方法 回顾性分析2007年至2012年接受化疗和IMRT的130例初治广泛期SCLC患者,化疗方案以顺铂、依托泊甙方案为主,放疗平均剂量为55.3 Gy(32~67 Gy)。RP采用常见不良反应事件评价标准(4.0版)进行评价,分析放疗结束后2级及以上RP发生的危险因素。通过单因素和多因素统计学方法分析预测因子。结果 全组中位随访时间37个月(4~66个月)。37例(28.5%)患者出现了≥2级的RP。单因素分析显示,年龄和剂量学参数(双肺V5、V10、V20、V30、平均肺剂量、双肺体积)与RP显著性相关;多因素分析显示,只有双肺V5是≥2级RP的独立危险因素。结论 多个临床和剂量学参数与RP的发生存在风险相关性,尤其是双肺V5。对化疗有效的广泛期SCLC患者行胸部放疗时,应综合考虑这些因素,适当降低V5的体积。
Abstract:
Objective To evaluate the clinical factors and dose-volume histogram-based factors as predictors of radiation pneumonitis(RP)in extensive-stage small cell lung cancer(ES-SCLC) patients treated with thoracic IMRT after chemotherapy. Methods Medical records of 130 ES-SCLC patients irradiated in our institution between 2007 and 2012 were retrospectively reviewed. Most patients received an initial chemotherapy regimen of combined carboplatin and etoposide or with cisplatin combined with etoposide. The median thoracic radiation dose was 55.3 Gy(32-67 Gy) with 1.8-2.3 Gy per fraction. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0, and RP at a grade of ≥Ⅱ is considered as a complication. Univariate and multivariate analyses were conducted to identify the predictive factors. Results Median follow-up period was 37 months (range:4-66 months). A total of 37 patients(28.5%) showed an RP grade of ≥Ⅱ. The univariate analysis revealed that in the entire population, age and many dosimetric parameters(V5, V10, V20, V30, mean lung dose, and total lung volume)were significantly associated with RP. By contrast, multivariate analysis showed that only V5 was significantly associated with RP. Conclusions In this study, a number of clinical and dosimetric factors are associated with a high risk of RP. However, V5 was the only significant factor associated with this condition. Multiple clinical and dosimetric factors should be considered in IMRT planning for ES-SCLC patients receiving thoracic radiotherapy after chemotherapy. It is proposed that V5 should be kept low to reduce the development of RP in ES-SCLC patients after chemotherapy.

参考文献/References:

[1] Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer[J]. Semin Oncol, 2001, 28(2 Suppl 4):S27-29. DOI:10.1016/S0093-7754(01)90075-2.
[2] Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23):5423-5431. DOI:10.1002/cncr.26206.
[3] Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual[M]. 7th ed. New York:Springer, 2010.
[4] Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer[J]. Lung Cancer, 2008, 59(2):232-239. DOI:10.1016/j.lungcan.2007.08.010.
[5] Eckert F, Müller AC, SCLC extensive disease-treatment guidance by extent or/and biology of response?[J]. Radiat Oncol, 2008, 3:33. DOI:10.1186/1748-717X-3-33.
[6] Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42. DOI:10.1016/S0140-6736(14)61085-0.
[7] 张文珏, 周宗玫, 陈东福, 等. 广泛期SCLC化疗后IMRT的疗效分析[J]. 中华放射肿瘤学杂志, 2016, 25(1):14-17. DOI:10. 3760/cma. j. issn. 1004-4221. 2016. 01. 004 Zhang WJ, Zhou ZM, Chen DF, et al. Clinical outcomes of extensive stage small cell lung cancer patients treated with intensive modified radiotherapy[J]. Chin J Radiat Oncol, 2016, 25(1):14-17.
[8] Shi A, Zhu G, Wu H, et al. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Radiat Oncol, 2010, 5:35. DOI:10.1186/1748-717X-5-35.
[9] Wen J, Liu H, Wang Q, et al. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy[J]. Eur J Cancer, 2014, 50(10):1706-1716. DOI:10.1016/j. ejca. 2014. 03. 008.
[10] Claude L, Pérol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer:clinical and dosimetric factors analysis[J]. Radiother Oncol, 2004, 71(2):175-181. DOI:10.1016/j. radonc. 2004. 02. 005.
[11] Mao J, Kocak Z, Zhou S, et al. The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response[J]. Int J Radiat Oncol Biol Phys, 2007, 67(5):1360-1369. DOI:10.1016/j. ijrobp. 2006. 11. 003.
[12] Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer(NSCLC)[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2):323-329.
[13] Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis(TRP) in patients with non-small-cell lung cancer(NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy(3D-CRT)[J]. Int J Radiat Oncol Biol Phys, 2006, 66(5):1399-1407. DOI:10.1016/j. ijrobp. 2006. 07. 1337.
[14] Yao B, Wang YD, Liu QZ. Radiation pneumonitis in non-small-cell lung cancer patients treated with helical tomotherapy[J]. Niger J Clin Pract, 2016, 19(1):25-29. DOI:10. 4103/1119-3077. 173709.
[15] Kim Y, Hong SE, Kong M, et al. Predictive factors for radiation pneumonitis in lung cancer treated with helical tomotherapy[J]. Cancer Res Treat, 2013, 45(4):295-302. DOI:10. 4143/crt. 2013. 45. 4. 295.
[16] Song CH, Pyo H, Moon SH, et al. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):651-658. DOI:10.1016/j. ijrobp. 2009. 08. 068.

相似文献/References:

[1]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[2]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
　Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[3]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
　Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[4]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
　Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
　LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[7]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
　ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[8]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
　YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[9]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
　LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[10]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
　LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[11]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[12]鲁胜男,冯彦林.18F-FDG PET-CT在评价肺癌化疗疗效中的应用[J].国际放射医学核医学杂志,2010,34(3):164.
　LU Sheng-nan,FENG Yan-lin.The application of 18F-FDG PET-CT in evaluation of the value of lung cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):164.
[13]付晓昉,王秀梅,许建春.放射性榄香烯三羰基铼配合物在荷小细胞肺癌裸鼠体内的分布及其对肿瘤的生长抑制作用[J].国际放射医学核医学杂志,2009,33(6):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
　FU Xiao-fang,WANG Xiu-mei,XU Jian-chun.Anti-tumor effect of elemene tricarbonyl rhenium-188 complex to small cell lung cancer and its biodistribution in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
[14]邓垒,张文珏,周宗玫,等.327例广泛期小细胞肺癌综合治疗的疗效分析[J].国际放射医学核医学杂志,2018,(1):1.[doi:10.3760/cma.j.issn.1673-4114.2018.01.001]
　Deng Lei,Zhang Wenjue,Zhou Zongmei,et al.Clinical outcomes of 327 patients with extensive-stage small cell lung cancer treated with chemotherapy combined with or without thoracic radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):1.[doi:10.3760/cma.j.issn.1673-4114.2018.01.001]

备注/Memo

备注/Memo:
收稿日期:2016-02-20。
基金项目:中国癌症基金会北京希望马拉松专项基金(LC2013A21)
通讯作者:周宗玫,Email:zhouzongmei2013@163.com
更新日期/Last Update: 1900-01-01